Europe's drugs regulator said on Wednesday its panel is reviewing Novavax's COVID-19 vaccine on a rolling basis, to speed up potential approvals as the region reels from surging infections due to new variations of the virus.
The human medicines committee of the European Medicines Agency will review data from ongoing trials of the U.S.-based company's vaccine, NVX-CoV2373, as they become available until there was enough for conditional approval, the regulator said. (https://bit.ly/2Len9jR)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.